Artis BioSolutions offers an integrated synthetic DNA and advanced therapy platform that produces enzymatically synthesized, plasmid‑free oDNA at gram scale for research and GMP use. The service delivers fully qualified DNA in as little as two weeks for RUO and 3‑4 weeks for GMP, then continues through downstream development and commercial‑grade manufacturing for modalities such as mRNA, gene editing, viral vectors, cell therapies, and vaccines, all under a single quality framework.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced therapy development is hindered by fragmented supply chains, reliance on legacy plasmid DNA, and multiple vendor handoffs that cause delays, increase contamination risk, and impede efficient progression from genetic concept to clinical-grade product.
Solution
Artis BioSolutions provides an integrated platform that merges proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing. Their truly synthetic oDNA is enzymatically generated at gram scale, free of plasmid DNA, and offered in both research‑use‑only (RUO) and GMP grades. Production timelines are two weeks for RUO material and three to four weeks for GMP‑ready material, enabling rapid transition from design to clinical material. The platform supplies application‑optimized linear dsDNA with specialized adapters, supporting modalities such as mRNA, gene‑editing constructs, viral vectors, cell therapies, and vaccines. Manufacturing sites in the United States and the European Union deliver consistent quality under a single regulatory framework, eliminating handoffs and knowledge loss across the development chain. End‑to‑end services accelerate advanced therapy medicinal products from synthetic DNA through GMP manufacturing, streamlining commercialization.
Target Audience
Primary customers are biotech and pharmaceutical companies developing advanced therapy medicinal products, as well as contract research organizations that require a single-source supplier for synthetic DNA and GMP manufacturing.
Features
- Enzymatic synthesis of truly synthetic oDNA at gram scale, eliminating plasmid dependency
- Availability in RUO (2‑week turnaround) and GMP (3‑4 week turnaround) grades
- Linear double‑stranded DNA formats with customized adapters tailored to therapeutic end‑goals
- Production capacity in both the United States (Watertown, MA) and the European Union (Bilbao, Spain) under GMP compliance
- Support for a broad spectrum of advanced therapy modalities: mRNA, gene editing, viral vectors, cell therapies, vaccines, and emerging biologics
- Integrated end‑to‑end service from synthetic DNA design through GMP manufacturing within a single quality framework